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While adult neurogenesis is considered to be restricted to the hippocampal dentate gyrus
(DG) and the subventricular zone (SVZ), recent studies in humans and rodents provide
evidence for newly generated neurons in regions generally considered as non-neurogenic,
e.g., the striatum. Stimulating dopaminergic neurotransmission has the potential to
enhance adult neurogenesis in the SVZ and the DG most likely via D2/D3 dopamine (DA)
receptors. Here, we investigated the effect of two distinct preferential D2/D3 DA agonists,
Pramipexole (PPX), and Ropinirole (ROP), on adult neurogenesis in the hippocampus and
striatum of adult naïve mice. To determine newly generated cells in the DG incorporating
5-bromo-2′-deoxyuridine (BrdU) a proliferation paradigm was performed in which two
BrdU injections (100mg/kg) were applied intraperitoneally within 12 h after a 14-days-DA
agonist treatment. Interestingly, PPX, but not ROP significantly enhanced the proliferation
in the DG by 42% compared to phosphate buffered saline (PBS)-injected control mice.
To analyze the proportion of newly generated cells differentiating into mature neurons, we
quantified cells co-expressing BrdU and Neuronal Nuclei (NeuN) 32 days after the last of
five BrdU injections (50mg/kg) applied at the beginning of 14-days DA agonist or PBS
administration. Again, PPX only enhanced neurogenesis in the DG significantly compared
to ROP- and PBS-injected mice. Moreover, we explored the pro-neurogenic effect of both
DA agonists in the striatum by quantifying neuroblasts expressing doublecortin (DCX)
in the entire striatum, as well as in the dorsal and ventral sub-regions separately. We
observed a significantly higher number of DCX+ neuroblasts in the dorsal compared to
the ventral sub-region of the striatum in PPX-injected mice. These results suggest that
the stimulation of hippocampal and dorsal striatal neurogenesis may be up-regulated by
PPX. The increased generation of neural cells, both in constitutively active and quiescent
neurogenic niches, might be related to the proportional higher D3 receptor affinity of PPX,
non-dopaminergic effects of PPX, or altered motor behavior.
Keywords: adult neurogenesis, dentate gyrus, striatum, dopamine agonist, dopamine receptor, neuroblast,
doublecortin, Parkinson’s disease
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INTRODUCTION
The generation of new neurons in the adult forebrain persists in
the subgranular zone (SGZ) of the dentate gyrus (DG) and the
subventricular zone (SVZ) of the lateral ventricles throughout
the mammalian lifespan (Sanai et al., 2004; Ming and Song,
2005; Spalding et al., 2013), including non-human primates and
humans (Eriksson et al., 1998; Ngwenya et al., 2006; Jabes et al.,
2010; Spalding et al., 2013). Several extrinsic factors regulate
proliferation and survival of neural precursor cells (NPCs)
such as growth factors, hormones, and neurotransmitters in
the “classical” constitutively active neurogenic niches (Brezun
and Daszuta, 1999; Kulkarni et al., 2002). In this regard, the
neurotransmitter dopamine (DA) plays a pivotal role (Winner
et al., 2006; Berg et al., 2011) since dopaminergic fibers directly
target hippocampal and SVZ NPCs (Hoglinger et al., 2004).
Dopaminergic neurons in the midbrain, particularly from the
substantia nigra pars compacta (SNc) and the ventral tegmental
area (VTA) innervate the hippocampal formation, as well as
the striatum (Bjorklund and Dunnett, 2007; Hoglinger et al.,
2014). The SGZ is mainly targeted by dopaminergic projections
of the caudal SNc (Hoglinger et al., 2004). In rodents, neurons
of the SNc project toward the dorsal and lateral striatum in a
topographically ordered medial-to-lateral arrangement forming
the ascending nigrostriatal pathway (Perrone-Capano and Di
Porzio, 2000). The previously defined non-neurogenic region,
the striatum, possesses the ability to generate neuroblasts
in response to cerebral ischemic stroke or traumatic injury
and in corresponding animals models (Luzzati et al., 2011;
Nato et al., 2015). Furthermore, striatal neurogenesis has also
been observed in adult non-human primates, such as the
squirrel monkey (Bedard et al., 2002). An indication for the
generation of new neurons in the striatum also derives from
a study in humans using a birth dating approach based on
the incorporation of nuclear-bomb-test-derived 14C in the DNA
of proliferating cells. Strikingly, a postnatal turnover of cells
was observed in the human striatum post-mortem (Ernst et al.,
2014).
Adult hippocampal neurogenesis is severely impaired in
neurodegenerative diseases, in particular Parkinson’s disease
(PD), the second most common neurodegenerative disorder
(Maj et al., 1997). One of the well-known hallmarks in PD
is the loss of dopaminergic neurons in the SNc with the
consecutive reduction of dopaminergic projections to the DG
and the striatum (Bernheimer et al., 1973; Hoglinger et al., 2004).
Although, the current treatment in PD is mainly constituted
Abbreviations: 6-OHDA, 6-hydroxydopamine; BDNF, brain derived growth
factor; BrdU, 5-bromo-2′-deoxyuridine; cAMP, cyclic adenosine monophosphate;
d, days; DA, dopamine; DAB, 3,3′-diaminobenzidine; DCX, doublecortin; DG,
dentate gyrus; D.Str., dorsal striatum; GCL, granule cell layer; GDNF, glial cell
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levodopa equivalent dose; NA, not applicable; NeuN, neuronal nuclei; NPCs,
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zone; SNc, substantia nigra pars compacta; SVZ, subventricular zone; TBS,
Tris-buffered saline; V.Str., ventral striatum; VTA, ventral tegmental area; wks,
weeks.
by levodopa and/or DA agonists to alleviate the diminished
dopaminergic tone within the striatum, a better understanding
of the micro-environmental signals regulating the generation
of NPCs will provide the possibility to regionally increase the
neural pool in the hippocampal formation and possibly in
quiescent neurogenic areas like the striatum. DA agonists act
by binding to different subsets of postsynaptic DA receptors
classified into two groups based on their intracellular signaling
properties, the D1- and the D2-like family. D1 and D5 receptors,
belonging to the D1-like family, are coupled to G-proteins and
thereby enhancing cyclic adenosine monophosphate (cAMP)
levels, whereas D2, D3, and D4 classified as D2-like receptor,
exert an opposite effect on cAMP resulting in decreased protein
kinase A (PKA) activity (Missale et al., 1998). Pramipexole (PPX)
is a D2-like selective, non-ergolinic DA agonist with 5- to 7-
fold higher affinity selectivity for the D3 receptor compared
to the D2 receptor and minimal activity on the D4 receptor
(Mierau et al., 1995; Dooley and Markham, 1998). Ropinirole
(ROP), another non-ergolinic DA agonist, has also a selectivity
for D2-like family receptors, but exhibit less specificity for the
D3 receptor in comparison to PPX (Tanaka et al., 2001). In
rodents D2-like family receptors are anatomically distributed
in telencephalic regions receiving dopaminergic afferents from
the VTA (A10), such as the hippocampus and the whole
striatum as observed by in situ hybridization and by qPCR
analysis of RNA extracted from hippocampal and striatal regions
(Sokoloff et al., 1990; Bouthenet et al., 1991; Mu et al.,
2011).
Several in vivo studies focused on dopaminergic stimulation
of adult neurogenesis within the SVZ or the SGZ in rodents
with dopaminergic lesions (Winner et al., 2006; Chiu et al.,
2015). Initially, there was evidence that levodopa restores
proliferation of NPCs within the SVZ after 6-hydroxydopamine
(6-OHDA) lesioning (Hoglinger et al., 2004). Furthermore, the
proliferation of NPCs was reduced in the SVZ of 6-OHDA-
lesioned rats (Winner et al., 2006), and consequently, PPX
administration induced the proliferation of NPCs in the SVZ of
6-OHDA lesioned rats (Winner et al., 2009). Recently, treatment
of levodopa and PPX restored decreased neurogenesis in the
DG and periglomerular layer of the olfactory bulb in mice
with bilateral intra-nigral 6-OHDA lesions (Chiu et al., 2015).
Since these studies were performed in lesioned animals only,
we explored the effects of the DA agonists, PPX and ROP,
frequently used for the treatment in PD patients, on adult
neurogenesis in the hippocampal SGZ and striatum of adult naïve
mice.
MATERIALS AND METHODS
Animals
Naïve female C57BL/6 mice aged 3 months (obtained from
Charles River Laboratories International, Inc.) were housed in
a 12 h light/12 h dark cycle and had free access to food and
water. All experiments were carried out in accordance with
the European Communities Council Directive of November,
24th 1986 (86/609/ EEC) and were approved by the local
governmental commission for animal health.
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Experimental Design
Proliferation of NPCs and the survival of newly generated
neurons in the DG were analyzed using three weight- and
age-matched groups of animals [proliferation group: phosphate
buffered saline (PBS), n = 5; PPX and ROP, n = 6; survival
group: PBS, n = 5; PPX and ROP, n = 7]. For both
designs, PPX, ROP, or PBS was administered by intraperitoneal
injections (i.p., dissolved in 100 µl PBS) once per day for 14
consecutive days: animals received either PPX 0.3mg/kg or
ROP 3.0mg/kg; the control animals were injected with 0.5%
PBS only. The dose selection for PPX and ROP was based
on previous studies where PPX treatment in a dose range
between 0.1 and 1mg/kg for up to 2 weeks was able to restore
lesion-induced dopaminergic deficits in mice on a functional,
biochemical, and structural level (Anderson et al., 2001; Jabes
et al., 2010). Furthermore, ROP treatment for up to 1 week
with doses between 0.5 and 3mg/kg attenuated lesion-induced
dopaminergic deficits in mice (Iida et al., 1999; Park et al.,
2013). In addition, we referred to the levodopa equivalent
dose (LED) representing an estimation of the DA agonist dose
able to produce a similar antiparkinsonian effect as 100mg
of levodopa in humans. The standardized LED for PPX and
ROP are 1 and 5mg, respectively (Yamada et al., 1990). The
2-week treatment period with DA agonists was also based on
previous studies reporting chronic DA agonist administration
being more effective in enhancing adult neurogenesis than acute
administration (Winner et al., 2009; Onoue et al., 2014; Takamura
et al., 2014).
To label proliferating cells in the forebrain, 5-bromo-2′-
deoxyuridine (BrdU) was injected i.p. twice on day 15 (100mg/kg
body weight; Figure 2A, proliferation paradigm). At day 15,
animals were deeply anesthetized and transcardially perfused
with 4% paraformaldehyde (PFA; Sigma) in 100 mM phosphate
buffer (PB), pH 7.4. In order to detect the survival of newly
generated cells in the DG, BrdU was administered once daily for
the first 5 days (50mg/kg, given in a volume of 100 µl) of the 14-
days DA agonist treatment in a second cohort of mice, and after
2 weeks animals were perfused at day 37 (Figure 3A, survival
paradigm).
Tissue Processing
Dissected brains were post-fixed in 4% PFA/PBS for 24 h,
placed in a solution of 30% sucrose in PBS and cut into 40-µm
coronal and sagittal sections using a sliding microtome (Leica,
Germany) on dry ice. The sections were stored in cryoprotectant
(ethylene glycol, glycerol, 0.1 M PB pH 7.4, 1:1:2 by volume)
at −20◦C until further processing for immunohistochemistry
or -fluorescence.
Immunohistochemistry and -Fluorescence
Immunostainings were performed as previously described (Kohl
et al., 2012). In order to detect BrdU, tissues were pre-treated with
formamide and HCl in order to denature DNA. Free-floating
sections in Tris-buffered saline (TBS: 0.15 M NaCl, 0.1 M Tris-
HCl, pH 7.5) were treated with 0.6% H2O2 for 30 min. Following
several washes in TBS, sections were blocked in 3% donkey
serum and 0.1% Triton-X100 (Sigma) diluted in TBS for 1 h and
incubated with primary antibodies in blocking solution overnight
at 4◦C. The primary antibodies used were monoclonal rat anti-
BrdU (1:500, AbD Serotec, Oxford, UK),monoclonalmouse anti-
Neuronal Nuclei (NeuN; 1:500, Millipore, Billerica, MA, USA),
and polyclonal goat anti-DCX (1:250, Santa Cruz Biotechnology,
CA, USA). For immunohistochemistry, tissues were treated
with biotin-conjugated species-specific secondary antibodies
followed by incubation with avidin-biotin-peroxidase complex
(1:100) and 3, 3′-diaminobenzidine (DAB) substrate (bothVector
Laboratories, Burlingame, CA, USA). For immunofluorescence,
donkey-derived anti-mouse and anti-rat secondary antibodies
were used conjugated with Alexa-568 and Alexa-488 or biotin
(1:500, Dianova, Hamburg, Germany), respectively (all 1:1000,
Invitrogen, Carlsbad, CA, USA). For all antibodies, control
stainings without primary antibody showed no signal.
Counting Procedures
Slides were blind-coded and all counting procedures were
performed on 40-µmsagittal sections. Every 6th section (240-µm
interval) was selected and processed for immunohistochemistry.
To analyze the number of BrdU+ cells in the granule cell
layer (GCL) of the DG, BrdU-labeled cells were exhaustively
counted on each section excluding the uppermost focal plane
(exclusion plane) and the obtained values multiplied by 6,
as an estimation of the total number of BrdU+ cells, both
for the proliferation and survival paradigm (Williams and
Rakic, 1988). All counting procedures and measurements of
reference DG volumes (measured in mm3) were conducted on a
light/fluorescence microscope (Zeiss AxioImager M2, Göttingen,
Germany) equipped with a semi-automatic stereology system
(Stereoinvestigator, MicroBrightField, Colchester, VT, USA) as
previously described (Kohl et al., 2012). The subsequent densities
of BrdU+ cells were calculated by dividing the number by
the DG volume for each animal. To quantify the number of
DCX+ neuroblasts in the entire striatum and consequently in
the dorsal and ventral sub-regions, we used sections at the
following coordinates: interaural lateral 1.44 and 1.08 mm. By
using this approach, the boundaries between the dorsal and
ventral striatum are anatomically well-defined by the anterior
commissure (see Figure 1, adopted from Franklin and Paxinos,
2013). The identical procedures as above described were applied
for the assessment of DCX+ cell numbers and striatal volumes.
All bright-field images were obtained using the samemicroscope,
as previously described.
To estimate the differentiation into a neuronal phenotype,
every 12th section was stained for BrdU and NeuN by
immunofluorescence and examined using a confocal laser
microscope (ZEISS LSM780, Göttingen, Germany) equipped
with a 40x PL APO oil objective and a pinhole setting that
corresponds to a focal plane of 2 µm or less. In the DG, 40
to 50 BrdU+ cells from each animal were analyzed, randomly
selected, and examined by moving through the z-axis of each
cell in order to exclude false double labeling. BrdU+ cells were
counted (newborn cells) and cells positive for both BrdU and
NeuN (BrdU+/NeuN+ double-positive cells, newborn neurons)
were assessed. The ratio of BrdU+/NeuN+ double positive
cells by BrdU+ cells was determined. Applying the ratio of
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FIGURE 1 | Topographical map of sagittal sections of adult mice
adopted from Franklin and Paxinos (2013). Regions analyzed within this
study are marked and include the dorsal and ventral striatum. Sections
analyzed between interaural lateral 1.44 and 1.08mm. D.Str., dorsal striatum;
V.Str., ventral striatum.
BrdU+/NeuN+ cells to the density of BrdU+ cells the number
of newborn neurons was calculated. Fluorescent images were
obtained using the identical confocal laser microscope (40x APO
objective).
Statistical Analysis
All values are expressed as mean ± standard error of the mean
(SEM). Statistical analysis was performed using one-way ANOVA
comparisons between treatment groups followed by Tukey’s
post-hoc analysis (Prism 5; GraphPad, San Diego, CA, USA).
For the analysis of DCX+ neuroblasts in the sub-regions of the
striatum, we used a classical linear regression with a square root
transformation of the dependent variable. Significance threshold
was assumed at p < 0.05.
RESULTS
PPX, but Not ROP Administration Results
in Increased Proliferation of NPCs in the
Hippocampal DG
In order to investigate the effect of two different DA agonists on
NPC proliferation in the adult DG, we compared the density of
newborn cells between PPX-, ROP-, and PBS-injected animals.
The groups were daily injected with PPX, ROP, or PBS for 14
days followed by two BrdU administrations at the same day prior
to perfusion (Figure 2A). We quantified the number of BrdU+
cells in the DG and calculated their density. PPX significantly
increased the number of BrdU+ cells compared to PBS-injected
mice by 42% [PPX: 15421.3± 544.2, ROP: 12722.9± 129.4, PBS:
10864.2 ± 827.1, F(2, 14) = 17.65, p < 0.001; Figures 2B–D;
Table 1]. In contrast, there was no significant effect on the
number of BrdU+ cells after administration of ROP (p > 0.05;
Figures 2B,E; Table 1). In addition, there was no effect of both
DA agonists on the DG volume [PPX: 0.183 ± 0.01, ROP: 0.174
± 0.01, PBS: 0.198± 0.02, F(2, 14) = 0.569, p > 0.05].
PPX Doubles Adult Neurogenesis in the
Murine DG
Next, we analyzed whether 14 days of administration with
PPX or ROP has a pro-neurogenic effect by determining the
survival of newborn neurons in the DG 32 days after the
last BrdU injection (Figures 3A,C–E). Therefore, we quantified
the density of surviving new DG cells and determined the
number of cells colabelling BrdU+ and the mature neuronal
marker NeuN+ in the DG. Interestingly, we observed that the
percentage of NeuN/BrdU double-labeled cells was significantly
increased in PPX-injected mice compared to ROP and PBS
[PPX: 88% ± 0.99, ROP: 73% ± 1.25, PBS: 70% ± 0.93,
F(2, 16) = 76.41, p < 0.05]. However, there was no effect of
ROP compared to PBS-injected mice. Calculating the density of
newborn neurons (BrdU+/NeuN+), PPX significantly enhanced
hippocampal neurogenesis by 91% in comparison with PBS-
injected mice [PPX: 11468.0± 1254.0, ROP: 7369.0± 797.8, PBS:
6014.0 ± 928.2, F(2, 16) = 7.305, PPX vs. PBS p < 0.01, PPX
vs. ROP p < 0.05; Figures 3B,F–H; Table 1]. In contrast, the
administration of ROP did not result in an increased number
of new neurons compared to PBS-injected mice (p > 0.05;
Figure 3B). Again, DG volumes were not different between
groups [PPX: 0.152 ± 0.01, ROP: 0.151 ± 0.01, PBS: 0.150 ±
0.008, F(2, 16) = 0.008, p > 0.05].
PPX Predominantly Promotes the
Generation of DCX+ Neuroblasts in the
Dorsal Striatum
We further investigated whether chronic DA agonist treatment
influences the number of neuroblasts within the striatum.
We quantified the number of DCX+ cells in the striatum of
animals from the survival paradigm. We observed that PPX
and ROP had no significant effect on the total number of
neuroblasts in the entire striatum compared with PBS-treated
mice [PPX: 257.1 ± 63.1, ROP: 157.7 ± 23.3, PBS: 134.4 ±
Frontiers in Neuroscience | www.frontiersin.org 4 March 2016 | Volume 10 | Article 77
Salvi et al. Dopaminergic Stimulation of Hippocampal and Striatal Neurogenesis
FIGURE 2 | Increased cell proliferation in the murine DG after chronic administration with PPX, but not after ROP treatment. (A) Proliferation paradigm.
3-month-old C57BL/6 received either i.p. PPX, ROP or PBS for 14 days. At day 14, animals were i.p. injected with BrdU (100mg/kg) twice to label proliferating cells.
Mice were perfused at day 15. (B) Quantification of BrdU+ cells in the DG revealed an increased density of proliferating cells after PPX compared to ROP and PBS.
Representative stainings of BrdU+ cells in the DG of PBS- (C), PPX- (D), and ROP-injected animals (E). Error bars represent mean ± SEM. One-way ANOVA followed
by Tukey’s post-hoc test, *p < 0.05. Scale bar: 50 µm (C–E).
FIGURE 3 | PPX only increases the generation of new neurons in the murine DG. (A) Survival paradigm. At the beginning, 3-month-old animals received PPX,
ROP or PBS i.p. for 14 days. During the first 5 days, all mice were i.p. injected with BrdU (50mg/kg). Animals were perfused 32 days after the last BrdU injection. (B)
Hippocampal neurogenesis (calculated density of BrdU+/NeuN+ neurons) was increased after PPX compared to PBS. No change in DG neurogenesis was observed
after ROP treatment. Representative stainings of BrdU+ in the DG of the hippocampus of PBS (C), PPX (D), and ROP (E) treated mice show a significant increase in
PPX-injected animals compared to ROP- and PBS-injected controls. Confocal microscopy depicts double-labeled BrdU+ (green)/NeuN+ (red) neurons in the
hippocampal DG of PBS (F), PPX (G), and ROP-injected mice (H). Error bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post-hoc test, *p < 0.05.
Scale bars: 20 µm (C–H).
13.9, F(2, 16) = 2.237, p > 0.05; Figures 4A–D; Table 1]. To
detect whether the dorsal striatum, being highly innervated by
dopaminergic projections of the SNc, was affected by PPX or
ROP administration to a greater extent in comparison to the
ventral striatum, we analyzed the number of DCX+ cells in both
sub-regions separately (Figure 1). To analyse the impact of PPX
and ROP simultaneously on the subregions (dorsal striatum,
PPX: 185.1 ± 41.6, ROP: 104.6 ± 16.5, PBS: 103.2 ± 6.1; ventral
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TABLE 1 | Summary of PPX and ROP treatment on hippocampal and striatal neurogenesis.
PBS PPX ROP
Hippocampal neurogenesis
Proliferation DG: density of BrdU+ cells 10864.2± 827.1 15421.3± 544.2###,++ 12722.9±129.4
Newly generated neurons DG: density of BrdU+/NeuN+ cells 6014.0± 928.2 11468.0± 1254.0##,+ 7369.0±797.8
Striatal Neuroblasts
DCX+ cells overall 134.4± 13.9 257.1± 63.1 157.7±23.3
DCX+ dorsal striatum 103.2± 6.1 185.1± 41.6# 104.6±16.5
DCX+ ventral striatum 31.2± 10.5 72.0± 23.6 53.1±24.1
PPX induced an increased number of dividing cells compared to ROP (by 21%) and PBS (by 42%) in the DG. A significant increased survival of newly generated neurons, identified by
BrdU/NeuN co-labeling, was observed in the DG of PPX-injected mice in comparison to ROP (56%) and PBS (91%). PPX-injected mice showed a non-significant increase of DCX+
neuroblasts in the entire striatum compared to PBS- or ROP-injected mice. Data is shown as mean ± SEM. Comparison between groups in the DG and the entire striatum was
performed by one-way ANOVA followed by Tukey’s post-hoc test and in the dorsal and ventral striatum by using a classical linear regression. BrdU, 5-bromo-2′-deoxyuridine; NeuN,
neuronal nuclei, DCX: doublecortin.
###Significance level p < 0.001 compared to PBS; ##Significance level p < 0.01 compared to PBS; #Significance level p < 0.05 compared to PBS; ++Significance level p < 0.01
compared to ROP; +Significance level p < 0.05 compared to ROP.
striatum, PPX: 72.0 ± 23.6, ROP: 53.1 ± 24. 1, PBS: 31.2 ±
10.5; Figure 4E), we fit a linear regression model on the number
of DCX+ cells. To gain normality in the dependent variable a
square root transformation was used. The effect of region was
significant with a coefficient of −4.73 (sd = 1.00, p < 0.001,
reference category: dorsal). In the categorical variable treatment
(reference category: PBS) the effect of PPX was significant with
a coefficient of 3.01 (sd = 1.28, p = 0.0246), while the effect of
ROP was not significant with a coefficient of 0.606 (sd = 1.28,
p = 0.639). The intercept of the model was 9.88. The volumes
of the entire striatum did not differ significantly between groups
[PPX: 3.065 ± 0.233, ROP: 2.788 ± 0.313, PBS: 2.962 ± 0.471,
F(2, 16) = 0.201, p > 0.05].
DISCUSSION
The chronic administration of the non-ergoline D2/D3-receptor
agonist PPX is able to strongly stimulate cell proliferation as
well as adult neurogenesis in the hippocampal DG of naive
mice. In contrast, the D2/D3-receptor agonist ROP shows no
pro-neurogenic effects, neither on cell proliferation nor on the
survival of newly generated DG neurons. Moreover, PPX only
resulted in an increased number of DCX+ neuroblasts in the
dorsal striatum suggesting a specific PPX mediated effect in the
mouse forebrain, both for constitutively active and quiescent
neurogenic niches.
While increasing experimental evidence supports the pro-
neurogenic effect of dopaminergic compounds such as levodopa
or DA agonists for enhancing adult neurogenesis in the SVZ
(Van Kampen et al., 2004; Borta and Hoglinger, 2007; Winner
et al., 2009) their role in stimulating adult hippocampal
neurogenesis is rather limited. In the present study we observed
that mice injected with PPX (0.3mg/kg) over 14 days showed
an increase of proliferating cells by 42% in the hippocampal
DG compared to PBS-injected controls. In contrast, chronic
ROP administration (3mg/kg) failed to stimulate hippocampal
cell proliferation. So far, two studies examined the effect
of DA agonists on cell proliferation in the hippocampus in
naïve rats: Onoue and colleagues described a reduction of
proliferating BrdU+ cells in the SGZ by 34% after administration
of PPX for 14 days in Wistar rats using a higher dosage
of PPX (1mg/kg; Onoue et al., 2014; Table 2). Another
study observed no changes in SGZ proliferation of Sprague
Dawley rats following PPX administration for 21 days at two
different dosages (0.3 or 1mg/kg; Takamura et al., 2014).
These apparent discrepancies between the present and previous
studies in enhancing adult hippocampal neurogenesis after
chronic PPX administration may be very likely explained by
species differences related to distinct characteristics of the
hippocampal neurogenic niche of mice and rats. Interestingly,
there is a species difference in relation to the duration
necessary for the maturation of new DG neurons (Snyder et al.,
2009).
Besides analyzing the effect of PPX on the proliferation of
hippocampal NPCs, the aim of this study was to determine
whether these newly generated cells were able to differentiate
toward a neuronal lineage. Here, we observed that PPX
administration significantly enhanced the proportion of neuronal
differentiation resulting in an increased density of newly
generated neurons by 91% in the DG of adult naïve mice
compared to PBS-injected controls. Again, ROP administration
failed to enhance hippocampal neurogenesis. The present effect
of PPX on the survival and differentiation of newly generated
neurons in the DG is in contrast to the previous study by
Takamura et al. in rats where PPX at two different dosages (0.3
and 1mg/kg) failed to enhance the survival of newly generated
cells (Takamura et al., 2014). However, the D3-receptor DA
agonist SKF38393 increased the survival of newly generated cells
by 53%, however without determining the cellular phenotype
(Takamura et al., 2014). While the majority of previous findings
are in contrast to the present study (see Table 2), it is very
likely that in particular species differences may account for the
divergent response to chronic DA agonist administration. This
notion is supported by our previous study in 6-OHDA lesioned
Sprague-Dawley rats, where chronic PPX administration was
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FIGURE 4 | PPX induces the generation of neuroblasts in the dorsal compared to the ventral striatum. Representative stainings of DCX+ cells in the
striatum showing a low number of neuroblasts in the PBS (A) and in the ROP group (C), and a higher number in the PPX group (B). Insert displays the region of
interest with DCX+ cells at higher magnification. (D–E) Quantification of DCX+ neuroblasts in the entire striatum, and separately in the dorsal vs. ventral striatal
sub-regions. No significant difference in the number of DCX+ cells was observed in the entire striatum for all groups (One-way ANOVA followed by Tukey’s post-hoc
test). In contrast, the analysis of striatal sub-regions by using a linear regression model revealed a significant effect of PPX, but not with ROP treatment. Please note
that the regression model was calculated based on the square root transformed numbers of DCX neuroblasts, whereas the untransformed numbers are displayed in
E. Error bars represent mean ± SEM. Scale bars: 50 µm (A–C), 10 µm (insert). D.Str, dorsal striatum; V.Str, ventral striatum.
TABLE 2 | Overview of studies addressing the effects of DA agonists on hippocampal neurogenesis in naïve rodents.
Study Species/background,
age, gender
BrdU dosage/paradigm Treatment Proliferation Survival
Present study C57BL/6 mice;
12wks, female
2 × 100mg/kg 24 h before
perfusion or 5 × 50mg/kg 32 d
before perfusion
0.3mg/kg PPX 14d 1d: 42% ⇑ (BrdU) 32 d: 91% ⇑
(BrdU/NeuN)
3mg/kg ROP 14d 1d:⇔ (BrdU) 32 d:⇔
(BrdU/NeuN)
Onoue et al.,
2014
Wistar rat; male 4 × 75mg/kg 6 h before
perfusion
1mg/kg PPX 14 d 1 d: ⇓ 34.2% (BrdU) NA
Takamura
et al., 2014
Sprague–Dawley
rat; 7 wks, male
1 × 75mg/kg 24 h before
perfusion or 21 d before
perfusion
0.3 or 1mg/kg PPX 21 d 1 d:⇔ (BrdU) 23 d:⇔ (BrdU)
10 or 30mg/kg SKF38393 21 d 1d:⇔ (BrdU) 23 d: 53% ⇑
(BrdU)
Values indicate the percentage increase or decrease of BrdU+ and BrdU+/NeuN+ cells in the DG compared to the control groups of the respective studies. The age of the animals
at the beginning of the experiments is given. ⇔; no effect vs. control, ⇑: increased effect vs. control; ⇓:: reduced effect vs. control. NA, not applicable, d, days, wks: weeks, BrdU,
5-bromo-2′-deoxyuridine; NeuN, neuronal nuclei.
not able to enhance adult neurogenesis in the hippocampal
DG (Winner et al., 2009). In support of this striking species
difference in regard to the response to dopaminergic stimuli,
a very recent study showed that PPX administration rescued
an impaired DG neurogenesis in 6-OHDA lesioned mice (Chiu
et al., 2015).
PPX, but not ROP had a strong pro-neurogenic effect on adult
hippocampal neurogenesis in mice although both compounds
are D2-like selective DA agonists. One possible explanation
for the different efficacy between both DA agonists may be
related to the distinct receptor binding profile of PPX with its
proportional higher affinity to the D3 receptor. In addition,
the chosen dosage for ROP may be too low, although recovery
of dopaminergic parameters after lesioning has been observed
in the range of 0.5–2.0mg/kg in mice (Iida et al., 1999; Park
et al., 2013). Furthermore, Li and colleagues demonstrated
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that PPX administered both at a low (0.1mg/kg) or high
dosage (0.5mg/kg) showed neuroprotective effects in a murine
PD model with an impaired ubiquitin-proteasome system (Li
et al., 2010). Interestingly, pretreatment with the D3 receptor
antagonist U99194 blocked the PPX-mediated neuroprotection
implying a selectivity of PPX for the D3 subtype (Li et al., 2010).
However, there is also evidence for the selectivity of ROP for
the D3 subtype over human D2 and D4 receptors based on
radio-ligand binding studies (Eden et al., 1991). Alternatively,
the effect of DA agonists on proliferation and differentiation
of hippocampal NPCs may be mediated by non-dopaminergic,
pro-neurogenic mechanisms, e.g., the stimulation of distinct
growth factors such as brain derived growth factor (BDNF) and
glial cell derived neurotrophic factor (GDNF; Du et al., 2005),
or altered physical activity (Yamada et al., 1990; Maj et al.,
1997).
The recent discovery of adult neurogenesis in the human
striatum and previously in the rodent striatum showed that
the generation of new neurons takes place in regions generally
considered as non-neurogenic (Bedard et al., 2002; Dayer et al.,
2005; Ernst et al., 2014; Inta et al., 2015). In the present study,
we addressed the question whether the DA agonists, PPX or
ROP, promote the generation of DCX+ neuroblasts in the
striatum of naïve adult C57BL/6 mice. Indeed, we observed
DCX+ neuroblasts throughout the striatum possibly constituting
an endogenous cellular pool with the potential to further
differentiate into neurons under physiological conditions, in the
context of a compromised striatal microenvironment or upon
specific exogenous stimuli. Interestingly, the number of DCX+
neuroblasts was significantly higher in the dorsal compared to
the ventral sub-region of the striatum in the PPX group only.
This dorsal-ventral gradient may reflect the fact that the dorsal
striatum receives the majority of dopaminergic projections from
the SNc (Haber, 2014).
Previously, a 10-fold increase in the number of BrdU+ cells
was observed in the dorsal striatum of adult Sprague-Dawley
rats following the intraventricular administration of the D3-
receptor agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin
(Van Kampen et al., 2004). However, systemic treatment with
PPX both in 6-OHDA and PBS medial forebrain bundle injected
rats did not increase the number of DCX+ neuroblasts in the
dorsal striatum (Winner et al., 2009). At present, it is still an
open question whether DCX+ neuroblasts or newly generated
neurons within the striatum evade from the adjacent SVZ or
are locally generated from an endogenous progenitor pool
within the striatal parenchyma. Interestingly and similar to the
post-mortem analysis in humans, we observed an increased
number of DCX+ neuroblasts in the striatum adjacent to the
SVZ in transgenic mouse and rat models of Huntington’s disease
(HD) suggesting that the damaged striatum may attract to some
extent immature neuroblasts from the adjacent SVZ (Kohl et al.,
2010; Kandasamy et al., 2015). However, it is important to note
that the lesioned striatum in PD models even after stimulation
with growth factors such as the epidermal growth factor or the
fibroblast growth factor-2 failed to provide a sufficient stimulus
for immature DCX+ neuroblasts to obtain a mature neuronal
phenotype (Winner et al., 2008). More recently, a long-lasting
inflammatory response within the striatum after lesioning was
observed and may explain the failure to differentiate into mature
neurons (Schlachetzki et al., 2014). Taken together, this study
provides evidence that species and the specific strain largely
matter when investigating effects of the generation of new
neurons in neurogenic and non-neurogenic regions following
compound treatment.
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